A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement.
The purpose of this study is to evaluate the tolerability of azacitidine in addition to Interfant-06 standard chemotherapy in infants with newly diagnosed acute lymphoblastic leukemia (ALL) with KMT2A gene rearrangement (KMT2A-R).
Participants will not be paid for their participation.
- IRB Number: 1704973993 (PHO-FALLON-COG-AALL15P1)
- Research Study Identifier: TX8311
- Principal Investigator: Batra Sandeep, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required